Mechanism of action of eukaryotic topoisomerase II and drugs targeted to the enzyme

被引:472
|
作者
Burden, DA
Osheroff, N
机构
[1] Vanderbilt Univ, Dept Biochem, Sch Med, Nashville, TN 37232 USA
[2] Vanderbilt Univ, Dept Med Oncol, Sch Med, Nashville, TN 37232 USA
关键词
anticancer drug; catalytic cycle; DNA cleavage complex; drug mechanism; topoisomerase II;
D O I
10.1016/S0167-4781(98)00132-8
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Topoisomerase II is a ubiquitous enzyme that is essential for the survival of all eukaryotic organisms and plays critical roles in virtually every aspect of DNA metabolism. The enzyme unknots and untangles DNA by passing an intact helix through a transient double-stranded break that it generates in a separate helix. Beyond its physiological functions, topoisomerase II is the target for some of the most active and widely prescribed anticancer drugs currently utilized for the treatment of human cancers. These drugs act in an insidious fashion and kill cells by increasing levels of covalent topoisomerase II-cleaved DNA complexes that are normally fleeting intermediates in the catalytic cycle of the enzyme. Over the past several years, we have made considerable strides in our understanding of the catalytic mechanism of topoisomerase II and the mechanism of action of drugs targeted to this enzyme. These advances have provided novel insights into the physiological functions of topoisomerase II and have led to the development of more efficacious chemotherapeutic regimens and novel anticancer drugs. Considering the importance of topoisomerase II to the eukaryotic cell and to cancer chemotherapy, it is essential to understand its enzymatic function and pharmacological properties. Therefore, this review will discuss the mechanism of action of eukaryotic topoisomerase II and topoisomerase II-targeted drugs. 0167-4781/98/$ see front matter (C) 1998 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:139 / 154
页数:16
相关论文
共 50 条
  • [31] Some fused heterocyclic compounds as eukaryotic topoisomerase II inhibitors
    Pinar, A
    Yurdakul, P
    Yildiz, I
    Temiz-Arpaci, O
    Acan, NL
    Aki-Sener, E
    Yalcin, I
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2004, 317 (02) : 670 - 674
  • [32] Stabilization of eukaryotic topoisomerase II-DNA cleavage complexes
    Wilstermann, AM
    Osheroof, N
    CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2003, 3 (03) : 321 - 338
  • [33] PHOSPHORYLATION OF DNA TOPOISOMERASE-II BY CASEIN KINASE-II - MODULATION OF EUKARYOTIC TOPOISOMERASE-II ACTIVITY INVITRO
    ACKERMAN, P
    GLOVER, CVC
    OSHEROFF, N
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1985, 82 (10) : 3164 - 3168
  • [34] Activation of the unfolded protein response is necessary and sufficient for reducing topoisomerase IIα protein levels and decreasing sensitivity to topoisomerase-targeted drugs
    Gray, MD
    Mann, M
    Nitiss, JL
    Hendershot, LM
    MOLECULAR PHARMACOLOGY, 2005, 68 (06) : 1699 - 1707
  • [35] INHIBITION OF EUKARYOTIC DNA TOPOISOMERASE-I AND TOPOISOMERASE-II ACTIVITIES BY INDOLOQUINOLINEDIONE DERIVATIVES
    RIOU, JF
    HELISSEY, P
    GRONDARD, L
    GIORGIRENAULT, S
    MOLECULAR PHARMACOLOGY, 1991, 40 (05) : 699 - 706
  • [36] ACTIVITIES OF EUKARYOTIC TOPOISOMERASE-I AND TOPOISOMERASE-II DURING THE CELL-CYCLE
    SAHAI, BM
    TRICOLI, JV
    MCCORMICK, PJ
    JARLINSKI, SJ
    BERTRAM, JS
    KOWALSKI, D
    CELL AND TISSUE KINETICS, 1985, 18 (02): : 217 - 217
  • [37] SIMULTANEOUS PURIFICATION OF DNA TOPOISOMERASE-I AND TOPOISOMERASE-II FROM EUKARYOTIC CELLS
    STRAUSFELD, U
    RICHTER, A
    PREPARATIVE BIOCHEMISTRY, 1989, 19 (01): : 37 - 48
  • [38] INHIBITORY EFFECTS OF QUINOLONES ON PROKARYOTIC AND EUKARYOTIC DNA TOPOISOMERASE-I AND TOPOISOMERASE-II
    MOREAU, NJ
    ROBAUX, H
    BARON, L
    TABARY, X
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1990, 34 (10) : 1955 - 1960
  • [39] NOVEL 1-8-BRIDGED CHIRAL QUINOLONES WITH ACTIVITY AGAINST TOPOISOMERASE-II - STEREOSPECIFICITY OF THE EUKARYOTIC ENZYME
    FROELICHAMMON, SJ
    MCGUIRK, PR
    GOOTZ, TD
    JEFSON, MR
    OSHEROFF, N
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1993, 37 (04) : 646 - 651
  • [40] A mutation in Escherichia coli DNA gyrase conferring quinolone resistance results in sensitivity to drugs targeting eukaryotic topoisomerase II
    Gruger, T
    Nitiss, JL
    Maxwell, A
    Zechiedrich, EL
    Heisig, P
    Seeber, S
    Pommier, Y
    Strumberg, D
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2004, 48 (12) : 4495 - 4504